Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 415 entries
Sorted by: Best Match Show Resources per page
Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial.

Therapeutic advances in psychopharmacology

Shoja Shafti S, Azizi Khoei A.
PMID: 27721970
Ther Adv Psychopharmacol. 2016 Oct;6(5):308-316. doi: 10.1177/2045125316656334. Epub 2016 Sep 14.

BACKGROUND: Several lines of evidence suggest that the cholinergic system may be disrupted in schizophrenia and so this may contribute to the cognitive impairments of schizophrenic patients. Because such deficits do not respond to neuroleptic treatment, different approaches have...

Cite
Shoja Shafti S, Azizi Khoei A. Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Ther Adv Psychopharmacol. 2016;6(5):308-316doi: 10.1177/2045125316656334.
Shoja Shafti, S., & Azizi Khoei, A. (2016). Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Therapeutic advances in psychopharmacology, 6(5), 308-316. https://doi.org/10.1177/2045125316656334
Shoja Shafti, Saeed, and Azizi Khoei, Abbas. "Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial." Therapeutic advances in psychopharmacology vol. 6,5 (2016): 308-316. doi: https://doi.org/10.1177/2045125316656334
Shoja Shafti S, Azizi Khoei A. Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Ther Adv Psychopharmacol. 2016 Oct;6(5):308-316. doi: 10.1177/2045125316656334. Epub 2016 Sep 14. PMID: 27721970; PMCID: PMC5036138.
Copy Download .nbib Format: NLM
Comprehensive treatment of dementia with Lewy bodies.

Alzheimer's research & therapy

Boot BP.
PMID: 26029267
Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015.

Dementia with Lewy bodies is an under-recognized disease; it is responsible for up to 20 % of all dementia cases. Accurate diagnosis is essential because the management of dementia with Lewy bodies is more complex than many neurodegenerative diseases....

Cite
Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther. 2015;7(1):45doi: 10.1186/s13195-015-0128-z.
Boot, B. P. (2015). Comprehensive treatment of dementia with Lewy bodies. Alzheimer's research & therapy, 7(1), 45. https://doi.org/10.1186/s13195-015-0128-z
Boot, Brendon P. "Comprehensive treatment of dementia with Lewy bodies." Alzheimer's research & therapy vol. 7,1 (2015): 45. doi: https://doi.org/10.1186/s13195-015-0128-z
Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015. PMID: 26029267; PMCID: PMC4448151.
Copy Download .nbib Format: NLM
Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.

JIMD reports

Barrett MJ, Shanker VL, Severt WL, Raymond D, Gross SJ, Schreiber-Agus N, Kornreich R, Ozelius LJ, Bressman SB, Saunders-Pullman R.
PMID: 24850235
JIMD Rep. 2014;16:31-8. doi: 10.1007/8904_2014_315. Epub 2014 May 22.

Mutations in glucosidase, beta, acid (GBA) are associated with cognitive impairment in Parkinson disease (PD) as well as dementia with Lewy bodies. For both of these diseases, dementia and hallucinations are typically treated with cholinesterase inhibitors and antipsychotics. However,...

Cite
Barrett MJ, Shanker VL, Severt WL, et al. Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease. JIMD Rep. 2014;16:31-8doi: 10.1007/8904_2014_315.
Barrett, M. J., Shanker, V. L., Severt, W. L., Raymond, D., Gross, S. J., Schreiber-Agus, N., Kornreich, R., Ozelius, L. J., Bressman, S. B., & Saunders-Pullman, R. (2014). Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease. JIMD reports, 1631-8. https://doi.org/10.1007/8904_2014_315
Barrett, M J, et al. "Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease." JIMD reports vol. 16 (2014): 31-8. doi: https://doi.org/10.1007/8904_2014_315
Barrett MJ, Shanker VL, Severt WL, Raymond D, Gross SJ, Schreiber-Agus N, Kornreich R, Ozelius LJ, Bressman SB, Saunders-Pullman R. Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease. JIMD Rep. 2014;16:31-8. doi: 10.1007/8904_2014_315. Epub 2014 May 22. PMID: 24850235; PMCID: PMC4221612.
Copy Download .nbib Format: NLM
Postponed effect of neostigmine on oxidative homeostasis.

Interdisciplinary toxicology

Pohanka M.
PMID: 26109890
Interdiscip Toxicol. 2014 Sep;7(3):134-8. doi: 10.2478/intox-2014-0018. Epub 2014 Dec 30.

Cholinesterases are enzymes able to hydrolyze the neurotransmitter acetylcholine and thus to terminate transmission. Once the enzymes are inhibited, excitotoxicity can appear in the adjacent cells. It is well known that oxidative stress is involved in the toxicity of...

Cite
Pohanka M. Postponed effect of neostigmine on oxidative homeostasis. Interdiscip Toxicol. 2014;7(3):134-8doi: 10.2478/intox-2014-0018.
Pohanka, M. (2014). Postponed effect of neostigmine on oxidative homeostasis. Interdisciplinary toxicology, 7(3), 134-8. https://doi.org/10.2478/intox-2014-0018
Pohanka, Miroslav. "Postponed effect of neostigmine on oxidative homeostasis." Interdisciplinary toxicology vol. 7,3 (2014): 134-8. doi: https://doi.org/10.2478/intox-2014-0018
Pohanka M. Postponed effect of neostigmine on oxidative homeostasis. Interdiscip Toxicol. 2014 Sep;7(3):134-8. doi: 10.2478/intox-2014-0018. Epub 2014 Dec 30. PMID: 26109890; PMCID: PMC4434106.
Copy Download .nbib Format: NLM
Treatment of Inappropriate Sexual Behavior in Dementia.

Current treatment options in neurology

De Giorgi R, Series H.
PMID: 27511056
Curr Treat Options Neurol. 2016 Sep;18(9):41. doi: 10.1007/s11940-016-0425-2.

OPINION STATEMENT: Inappropriate sexual behavior (ISB) is a relatively common and potentially disruptive form of behavior in people with dementia. It can cause considerable distress and put placements and people at risk. Yet it is poorly researched and understood....

Cite
De Giorgi R, Series H. Treatment of Inappropriate Sexual Behavior in Dementia. Curr Treat Options Neurol. 2016;18(9):41doi: 10.1007/s11940-016-0425-2.
De Giorgi, R., & Series, H. (2016). Treatment of Inappropriate Sexual Behavior in Dementia. Current treatment options in neurology, 18(9), 41. https://doi.org/10.1007/s11940-016-0425-2
De Giorgi, Riccardo, and Series, Hugh. "Treatment of Inappropriate Sexual Behavior in Dementia." Current treatment options in neurology vol. 18,9 (2016): 41. doi: https://doi.org/10.1007/s11940-016-0425-2
De Giorgi R, Series H. Treatment of Inappropriate Sexual Behavior in Dementia. Curr Treat Options Neurol. 2016 Sep;18(9):41. doi: 10.1007/s11940-016-0425-2. PMID: 27511056; PMCID: PMC4980403.
Copy Download .nbib Format: NLM
Natural sesquiterpen lactones as acetylcholinesterase inhibitors.

Anais da Academia Brasileira de Ciencias

Hajimehdipoor H, Mosaddegh M, Naghibi F, Haeri A, Hamzeloo-Moghadam M.
PMID: 24838542
An Acad Bras Cienc. 2014 Jun;86(2):801-806. doi: 10.1590/0001-3765201420130005. Epub 2014 May 14.

Background and the purpose of the study: The amount of elder people who suffer from Alzheimer disease is continuously increasing every year. Cholinesterase inhibitors have shown to be effective in alleviating the symptoms of the disease, thus opening a...

Cite
Hajimehdipoor H, Mosaddegh M, Naghibi F, et al. Natural sesquiterpen lactones as acetylcholinesterase inhibitors. An Acad Bras Cienc. 2014;86(2):801-806doi: 10.1590/0001-3765201420130005.
Hajimehdipoor, H., Mosaddegh, M., Naghibi, F., Haeri, A., & Hamzeloo-Moghadam, M. (2014). Natural sesquiterpen lactones as acetylcholinesterase inhibitors. Anais da Academia Brasileira de Ciencias, 86(2), 801-806. https://doi.org/10.1590/0001-3765201420130005
Hajimehdipoor, Homa, et al. "Natural sesquiterpen lactones as acetylcholinesterase inhibitors." Anais da Academia Brasileira de Ciencias vol. 86,2 (2014): 801-806. doi: https://doi.org/10.1590/0001-3765201420130005
Hajimehdipoor H, Mosaddegh M, Naghibi F, Haeri A, Hamzeloo-Moghadam M. Natural sesquiterpen lactones as acetylcholinesterase inhibitors. An Acad Bras Cienc. 2014 Jun;86(2):801-806. doi: 10.1590/0001-3765201420130005. Epub 2014 May 14. PMID: 24838542.
Copy Download .nbib Format: NLM
Cholinesterase inhibitors from botanicals.

Pharmacognosy reviews

Ahmed F, Ghalib RM, Sasikala P, Ahmed KK.
PMID: 24347920
Pharmacogn Rev. 2013 Jul;7(14):121-30. doi: 10.4103/0973-7847.120511.

Alzheimer's disease (AD) is a progressive neurodegenerative disease, wherein a progressive loss of cholinergic synapses occurs in hippocampus and neocortex. Decreased concentration of the neurotransmitter, acetylcholine (ACh), appears to be critical element in the development of dementia, and the...

Cite
Ahmed F, Ghalib RM, Sasikala P, et al. Cholinesterase inhibitors from botanicals. Pharmacogn Rev. 2013;7(14):121-30doi: 10.4103/0973-7847.120511.
Ahmed, F., Ghalib, R. M., Sasikala, P., & Ahmed, K. K. (2013). Cholinesterase inhibitors from botanicals. Pharmacognosy reviews, 7(14), 121-30. https://doi.org/10.4103/0973-7847.120511
Ahmed, Faiyaz, et al. "Cholinesterase inhibitors from botanicals." Pharmacognosy reviews vol. 7,14 (2013): 121-30. doi: https://doi.org/10.4103/0973-7847.120511
Ahmed F, Ghalib RM, Sasikala P, Ahmed KK. Cholinesterase inhibitors from botanicals. Pharmacogn Rev. 2013 Jul;7(14):121-30. doi: 10.4103/0973-7847.120511. PMID: 24347920; PMCID: PMC3841990.
Copy Download .nbib Format: NLM
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Neurology

Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL.
PMID: 11342679
Neurology. 2001 May 08;56(9):1154-66. doi: 10.1212/wnl.56.9.1154.

OBJECTIVE: To define and investigate key issues in the management of dementia and to make literature-based treatment recommendations.METHODS: The authors searched the literature for four clinical questions: 1) Does pharmacotherapy for cognitive symptoms improve outcomes in patients with dementia?...

Cite
Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1154-66doi: 10.1212/wnl.56.9.1154.
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., & Cummings, J. L. (2001). Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56(9), 1154-66. https://doi.org/10.1212/wnl.56.9.1154
Doody, R S, et al. "Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology." Neurology vol. 56,9 (2001): 1154-66. doi: https://doi.org/10.1212/wnl.56.9.1154
Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 May 08;56(9):1154-66. doi: 10.1212/wnl.56.9.1154. PMID: 11342679.
Copy Download .nbib Format: NLM
Diffuse Lewy Body Disease.

Current treatment options in neurology

Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA.
PMID: 11581527
Curr Treat Options Neurol. 2001 Nov;3(6):507-518. doi: 10.1007/s11940-001-0013-x.

Diffuse Lewy body disease (DLB) is a neurodegenerative disorder characterized by dementia, fluctuations in mental status, hallucinations, and parkinsonism. Diffuse Lewy body disease is the second most common cause of dementia, following Alzheimer's disease. The treatment of DLB includes...

Cite
Zesiewicz TA, Baker MJ, Dunne PB, et al. Diffuse Lewy Body Disease. Curr Treat Options Neurol. 2001;3(6):507-518doi: 10.1007/s11940-001-0013-x.
Zesiewicz, T. A., Baker, M. J., Dunne, P. B., & Hauser, R. A. (2001). Diffuse Lewy Body Disease. Current treatment options in neurology, 3(6), 507-518. https://doi.org/10.1007/s11940-001-0013-x
Zesiewicz, Theresa A., et al. "Diffuse Lewy Body Disease." Current treatment options in neurology vol. 3,6 (2001): 507-518. doi: https://doi.org/10.1007/s11940-001-0013-x
Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA. Diffuse Lewy Body Disease. Curr Treat Options Neurol. 2001 Nov;3(6):507-518. doi: 10.1007/s11940-001-0013-x. PMID: 11581527.
Copy Download .nbib Format: NLM
Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease.

Evidence-based mental health

Lahiri DK, Farlow MR.
PMID: 12893805
Evid Based Ment Health. 2003 Aug;6(3):94. doi: 10.1136/ebmh.6.3.94.

No abstract available.

Cite
Lahiri DK, Farlow MR. Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease. Evid Based Ment Health. 2003;6(3):94doi: 10.1136/ebmh.6.3.94.
Lahiri, D. K., & Farlow, M. R. (2003). Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease. Evidence-based mental health, 6(3), 94. https://doi.org/10.1136/ebmh.6.3.94
Lahiri, Debomoy K, and Farlow, Martin R. "Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease." Evidence-based mental health vol. 6,3 (2003): 94. doi: https://doi.org/10.1136/ebmh.6.3.94
Lahiri DK, Farlow MR. Review: cholinesterase inhibitors have a modest effect on neuropsychiatric and functional outcomes in Alzheimer's disease. Evid Based Ment Health. 2003 Aug;6(3):94. doi: 10.1136/ebmh.6.3.94. PMID: 12893805.
Copy Download .nbib Format: NLM
Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics.

Drugs of today (Barcelona, Spain : 1998)

Cacabelos R, Alvarez A, Lombardi V, Fernández-Novoa L, Corzo L, Pérez P, Laredo M, Pichel V, Hernández A, Varela M, Figueroa J, Prous J, Windisch M, Vigo C.
PMID: 12861345
Drugs Today (Barc). 2000 Jul;36(7):415-99.

For the past 20 years the scientific community and the pharmaceutical industry have been searching for treatments to neutralize the devastating effects of Alzheimer disease (AD). During this period important changes in the etiopathogenic concept of AD have occurred...

Cite
Cacabelos R, Alvarez A, Lombardi V, et al. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today (Barc). 2000;36(7):415-99
Cacabelos, R., Alvarez, A., Lombardi, V., Fernández-Novoa, L., Corzo, L., Pérez, P., Laredo, M., Pichel, V., Hernández, A., Varela, M., Figueroa, J., Prous, J., Windisch, M., & Vigo, C. (2000). Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs of today (Barcelona, Spain : 1998), 36(7), 415-99.
Cacabelos, R, et al. "Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics." Drugs of today (Barcelona, Spain : 1998) vol. 36,7 (2000): 415-99.
Cacabelos R, Alvarez A, Lombardi V, Fernández-Novoa L, Corzo L, Pérez P, Laredo M, Pichel V, Hernández A, Varela M, Figueroa J, Prous J, Windisch M, Vigo C. Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today (Barc). 2000 Jul;36(7):415-99. PMID: 12861345.
Copy Download .nbib Format: NLM
Review: cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia.

Evidence-based mental health

Kaduszkiewicz H, Hoffmann F.
PMID: 18952962
Evid Based Ment Health. 2008 Nov;11(4):113. doi: 10.1136/ebmh.11.4.113.

No abstract available.

Cite
Kaduszkiewicz H, Hoffmann F. Review: cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia. Evid Based Ment Health. 2008;11(4):113doi: 10.1136/ebmh.11.4.113.
Kaduszkiewicz, H., & Hoffmann, F. (2008). Review: cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia. Evidence-based mental health, 11(4), 113. https://doi.org/10.1136/ebmh.11.4.113
Kaduszkiewicz, Hanna, and Hoffmann, Falk. "Review: cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia." Evidence-based mental health vol. 11,4 (2008): 113. doi: https://doi.org/10.1136/ebmh.11.4.113
Kaduszkiewicz H, Hoffmann F. Review: cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia. Evid Based Ment Health. 2008 Nov;11(4):113. doi: 10.1136/ebmh.11.4.113. PMID: 18952962.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 415 entries